Novartis AG Sponsored ADR pharmaceutical (NVS.US) $2 billion acquisition of Excellergy to strengthen the food allergy and immune disease track.

Novartis AG Sponsored ADR pharmaceuticals (NVS.US) has agreed to acquire biotechnology company Excellergy Inc. for up to $2 billion, strengthening its product portfolio in the treatment of food allergies and other immune diseases. The Swiss pharmaceutical company stated that the deal includes upfront and milestone payments, and is expected to be completed in the second half of this year, subject to various conditions including regulatory approval. The core asset of this acquisition is the innovative candidate drug Exl-111 developed by Excellergy. As a novel triple-functional effector cell response inhibitor (ECRI), Exl-111 primarily targets the IgE (immunoglobulin E) mediated immune pathway. IgE is a key factor in treating various allergic diseases, triggering an exaggerated response in the body to harmless substances. Compared to existing anti-IgE therapies, this candidate drug has a stronger signal inhibition capacity in design, capable of rapidly and deeply blocking allergic reactions. Currently in the early stages of clinical trials, the drug is expected to be a potential treatment option for various diseases such as food allergies, chronic spontaneous urticaria, chronic inducible urticaria, and allergic asthma, according to the company. With the addition of Excellergy, Novartis AG Sponsored ADR pharmaceuticals will have a more diversified product portfolio in the field of allergic diseases. As the global prevalence of allergic diseases continues to rise, there is an increasing demand in the market for longer-lasting and safer biologics. If Exl-111 can successfully enter late-stage clinical trials and receive approval for market launch, it will have a synergistic effect with Novartis AG Sponsored ADR pharmaceuticals' existing immune pipeline. It is worth mentioning that in recent years, as several top-selling old drugs face competition from generic drugs, Novartis AG Sponsored ADR pharmaceuticals is strengthening its research pipeline through intensive acquisitions, which is expected to result in its first profit decline in at least six years. Just a week before this deal was reached, Novartis AG Sponsored ADR pharmaceuticals announced the acquisition of Synnovation Therapeutics for $3 billion, to enhance its asset reserves in the field of oncology. In addition, Novartis AG Sponsored ADR pharmaceuticals also announced one of its largest investments last October - the acquisition of Avidity Biosciences for $12 billion, followed by a series of deals for allergic diseases and breast cancer drugs.